Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer's Disease Trials (CTAD 2020)

Background: Drug development for Alzheimer’s disease (AD) is increasingly expensive and time-consuming.  To decrease the high failure rate of these trials, it will be necessary to improve clinical trial design by reducing total trial size and/or recruitment time.  Randomized controlled trials (RCTs) have long been the gold-standard among clinical trial designs, even though they can be very inefficient. The volume of clinical trials provides an opportunity to improve the efficiency of AD trials, which has been highlighted by the FDA in a number of communications. With data collected from the control groups of many prior AD trials and state-of-the-art statistical methods, we have developed machine learning (ML) technology to comprehensively model the progression of control subjects. Our model can generate digital twins, which are digital subject records generated from the baseline data of actual subjects in a trial. These digital twins show the potential outcomes of individual subjects had they received a placebo.


Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

How will AI transform the future of medicine?

White Papers

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs

Both methods reduce control arm sizes, but only digital twins control for bias.
A Phase 2 study on crenezumab in mild-to-moderate AD was used to retrospectively assess the validity of Unlearn's approach for AD clinical trials.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.